The medical technology company reported a notable insider sale as shares returned 35% over the past year.

Heartflow Inc. (NASDAQ:HTFL) climbed by 46 percent week-on-week, making it the fourth-highest gainer on the stock market last week, thanks to its strong revenue performance that helped bolster its growth outlook for the full-year period. In an updated report during the week, the listed firm said that it grew its revenues by 48 percent in […]

HeartFlow stock has surged over the past month, yet the valuation checks currently lean expensive rather than pointing to a clear bargain. That mix of strong recent returns and a low value score raises questions about how much optimism is already reflected in the share price. HeartFlow has returned 69.1% over the past month, which sets a high bar for future performance to justify the current valuation. Expectations around continued adoption of HeartFlow's AI platform for diagnosing coronary...

HeartFlow (HTFL) moved after its second quarter 2026 report, which paired higher sales with a continued net loss, along with a raised full year revenue outlook that lifted investor attention on the stock. See our latest analysis for HeartFlow. HeartFlow has seen sharp share price momentum around these results, with a 1 day share price return of 35.7% and a 30 day share price return of 69.1%, helping lift the stock to US$42.08 and contributing to a 35% 1 year total shareholder return. If the...

HeartFlow has just seen its fair value estimate move from US$37.00 to about US$42.13, which puts the current analyst price target conversation firmly in the low to mid US$40s. Recent Street research ties these updated targets to Q2 results, new guidance for 2026, fresh product and clinical data, and index changes that all feed into revised valuation frameworks. As you read on, you will see how this shifting narrative fits together and what to watch as the story develops from here. Stay...

Heartflow Inc. (NASDAQ:HTFL) climbed to a fresh all-time high on Friday, as investors took heart from its strong revenues in the second quarter of the year that helped boost its growth outlook for the full-year period. In intra-day trading, the stock climbed to its highest price of $42.99 before trimming gains to end the session […]

The healthcare technology leader is using artificial intelligence to detect coronary artery disease early.

Heartflow stock broke out Friday, helped by an "outsized" guidance raise and second-quarter beat.

Moby summary of Heartflow, Inc. Common Stock's Q2 2026 earnings call

HeartFlow Inc (HTFL) raises full-year guidance as Plaque revenue beats expectations and gross margins expand to 83.3%.

Heartflow (NASDAQ:HTFL) reported second-quarter revenue of $64.1 million, up 48% from a year earlier, as growth in its Plaque Analysis offering, durable FFR-CT utilization and continued expansion of the coronary CT angiography, or CCTA, market supported results. U.S. revenue rose 51% to $59.6 milli

HeartFlow (HTFL) delivered earnings and revenue surprises of +50.00% and +12.96%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Roblox downgraded, Quanta Services upgraded: Wall Street's top analyst calls

After a week of wild swings that rattled portfolios and left investors guessing, Wall Street analysts are already reshuffling their ratings on Friday morning, with some surprising cuts and upgrades across sectors from utilities to gaming that could reshape how you think about your positions.

Pulmonx (LUNG) delivered earnings and revenue surprises of +14.29% and +2.34%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

NZS shifts capital toward AI infrastructure and healthcare leaders

The medical technology company reported a notable insider sale in recent filings.